{
    "organizations": [],
    "uuid": "3f813e141c2321f6fc8223923f4039c294134a3f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-asterias-provides-update-for-its-a/brief-asterias-provides-update-for-its-ast-opc1-phase-1-2aclinical-trial-idUSASB0C83O",
    "ord_in_thread": 0,
    "title": "BRIEF-Asterias Provides Update For Its AST-OPC1 Phase 1/2A Clinical Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - Asterias Biotherapeutics Inc:\n* ASTERIAS PROVIDES UPDATE FOR ITS AST-OPC1 PHASE 1/2A CLINICAL TRIAL IN SEVERE SPINAL CORD INJURY\n* ASTERIAS BIOTHERAPEUTICS INC - ‍RESULTS TO DATE SHOW AST-OPC1‘S FAVORABLE SAFETY PROFILE, POTENTIAL FOR CELL ENGRAFTMENT AND IMPROVED MOTOR FUNCTION​\n* ASTERIAS BIOTHERAPEUTICS INC - ‍MULTIPLE ADDITIONAL DATA READOUTS FROM SCISTAR STUDY EXPECTED IN 2018 INTO Q1 OF 2019​\n* ASTERIAS BIOTHERAPEUTICS INC - ‍THERE HAVE BEEN NO SERIOUS, UNEXPECTED, ADVERSE EVENTS RELATED TO AST-OPC1, INJECTION PROCEDURE​\n* ASTERIAS BIOTHERAPEUTICS INC - ‍TO DATE, THERE HAVE BEEN NO SERIOUS ADVERSE EVENTS RELATED TO AST-OPC1 CELLS​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-01T06:01:00.000+02:00",
    "crawled": "2018-03-01T20:58:21.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "asterias",
        "biotherapeutics",
        "inc",
        "asterias",
        "provides",
        "update",
        "phase",
        "clinical",
        "trial",
        "severe",
        "spinal",
        "cord",
        "injury",
        "asterias",
        "biotherapeutics",
        "inc",
        "date",
        "show",
        "favorable",
        "safety",
        "profile",
        "potential",
        "cell",
        "engraftment",
        "improved",
        "motor",
        "asterias",
        "biotherapeutics",
        "inc",
        "additional",
        "data",
        "readout",
        "scistar",
        "study",
        "expected",
        "q1",
        "asterias",
        "biotherapeutics",
        "inc",
        "serious",
        "unexpected",
        "adverse",
        "event",
        "related",
        "injection",
        "asterias",
        "biotherapeutics",
        "inc",
        "date",
        "serious",
        "adverse",
        "event",
        "related",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}